Is Apellis Pharmaceuticals' FDA Win Just the Beginning?
ApellisApellis(US:APLS) 247Wallst·2026-01-17 10:36

Core Insights - Apellis Pharmaceuticals (APLS) received FDA approval for EMPAVELI targeting C3 glomerulopathy and IC-MPGN, with the stock trading around $28 at the time of approval [1] Company Summary - The FDA approval of EMPAVELI marks a significant milestone for Apellis Pharmaceuticals, potentially impacting its market position and stock performance [1]